Business Wire

Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...

Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...
News Medical

High-accuracy AAV capsid measurement made simple with the Vericheck ddPCR kit

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
Morningstar

Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits

The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles. Dr Ruizhi Wang, CEO and Founder, Abselion, said: ...
EurekAlert!

Enhanced inner ear tropism of Adeno-Associated Virus (AAV) vectors via peptide display on AAV1 capsid

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...
News Medical

Precise AAV capsid measurements with Vericheck ddPCR for gene therapy applications

Quantification of empty and full adeno-associated virus (AAV) capsids is crucial for maximizing viral vectors used in gene therapy. The launch of the Vericheck ddPCR Empty-Full Capsid Kit expands this ...
Business Wire

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid ...
Nasdaq

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Seeking Alpha

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first ...
Morningstar

PackGene to Offer Barcoded High-Throughput AAV Capsid Screening Kits Through Strategic License Agreement with Children's Medical Research Institute

PackGene to Offer Barcoded High-Throughput AAV Capsid Screening Kits Through Strategic License Agreement with Children's Medical Research Institute Provided by PR Newswire Aug 26, 2025, 4:30:00 AM ...